Beth Barber

2.6k total citations
83 papers, 2.1k citations indexed

About

Beth Barber is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Beth Barber has authored 83 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 21 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Beth Barber's work include Colorectal Cancer Treatments and Studies (22 papers), Cutaneous Melanoma Detection and Management (20 papers) and Melanoma and MAPK Pathways (18 papers). Beth Barber is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), Cutaneous Melanoma Detection and Management (20 papers) and Melanoma and MAPK Pathways (18 papers). Beth Barber collaborates with scholars based in United States, United Kingdom and Switzerland. Beth Barber's co-authors include Zhongyun Zhao, Maureen J. Lage, Harry A. Guess, Floyd J. Fowler, Michael P. O’Leary, William R. Lenderking, Michael J. Barry, Sue Gao, David J. Harrison and Joanne Waldstreicher and has published in prestigious journals such as Journal of Clinical Oncology, Ophthalmology and The Journal of Urology.

In The Last Decade

Beth Barber

81 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beth Barber United States 24 712 418 322 311 304 83 2.1k
Shari Goldfarb United States 26 1.3k 1.8× 387 0.9× 289 0.9× 104 0.3× 734 2.4× 96 3.1k
Jennifer Sung United States 22 356 0.5× 231 0.6× 307 1.0× 146 0.5× 80 0.3× 46 1.6k
Peg Esper United States 18 757 1.1× 702 1.7× 205 0.6× 146 0.5× 98 0.3× 30 1.8k
Maurizio Belfiglio Italy 23 275 0.4× 316 0.8× 184 0.6× 90 0.3× 344 1.1× 48 2.0k
Alan S. Morrison United States 30 943 1.3× 712 1.7× 668 2.1× 53 0.2× 67 0.2× 56 2.8k
Ryszard Gellert Poland 14 308 0.4× 374 0.9× 270 0.8× 35 0.1× 70 0.2× 48 1.7k
Eberhard Varenhorst Sweden 31 777 1.1× 1.9k 4.5× 414 1.3× 169 0.5× 66 0.2× 102 2.7k
Roland T. Skeel United States 16 856 1.2× 401 1.0× 383 1.2× 117 0.4× 76 0.3× 54 2.9k
Peter T. Silberstein United States 21 740 1.0× 319 0.8× 236 0.7× 62 0.2× 53 0.2× 172 1.8k
Shawn Malone Canada 31 1.3k 1.8× 2.7k 6.4× 446 1.4× 67 0.2× 111 0.4× 168 4.5k

Countries citing papers authored by Beth Barber

Since Specialization
Citations

This map shows the geographic impact of Beth Barber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Barber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Barber more than expected).

Fields of papers citing papers by Beth Barber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Barber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Barber. The network helps show where Beth Barber may publish in the future.

Co-authorship network of co-authors of Beth Barber

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Barber. A scholar is included among the top collaborators of Beth Barber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Barber. Beth Barber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ma, Qiufei, Mark Shilkrut, Zhongyun Zhao, et al.. (2018). Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. BMC Cancer. 18(1). 145–145. 16 indexed citations
3.
Graham, Christopher N., Gregory A. Maglinte, Lee S. Schwartzberg, et al.. (2016). Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical Therapeutics. 38(6). 1376–1391. 9 indexed citations
4.
Ma, Qiufei, et al.. (2016). Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.. PubMed. 9(4). 203–13. 33 indexed citations
5.
Zhao, Zhongyun, et al.. (2015). Economic burden of toxicities associated with treating metastatic melanoma in eight countries. The European Journal of Health Economics. 18(1). 49–58. 42 indexed citations
6.
Song, Xue, et al.. (2015). Overall survival in patients with metastatic melanoma. Current Medical Research and Opinion. 31(5). 987–991. 53 indexed citations
7.
Graham, Christopher N., Guy Hechmati, Marwan Fakih, et al.. (2015). Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-typeRASmetastatic colorectal cancer. Journal of Medical Economics. 18(8). 619–628. 7 indexed citations
8.
Barlev, Arie, et al.. (2015). Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom. Health and Quality of Life Outcomes. 13(1). 181–181. 12 indexed citations
9.
Farr, A., et al.. (2014). Medical Costs by Disease Stage in Medicare Patients with Melanoma. Value in Health. 17(3). A78–A78. 1 indexed citations
10.
Ma, Qiang, Zhongyun Zhao, & Beth Barber. (2014). Hospital Costs of Adverse Events in Patients with Metastatic Melanoma. Value in Health. 17(3). A82–A82. 1 indexed citations
11.
Burudpakdee, Chakkarin, et al.. (2011). Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies. Journal of Medical Economics. 15(2). 371–377. 17 indexed citations
12.
Emons, Matthew F, Bonnie B. Dean, Hsing-Ting Yu, et al.. (2011). PCN9 Adverse Events Among Patients with Metastatic Colorectal Cancer Treated with Monoclonal antibodies in Clinical Practice. Value in Health. 14(7). A435–A435. 2 indexed citations
13.
14.
Zhao, Zhongyun, Elise M. Pelletier, Beth Barber, et al.. (2011). Major Surgery in Patients with Metastatic Colorectal Cancer in Western Europe. Journal of Gastrointestinal Cancer. 43(3). 456–461. 10 indexed citations
15.
Song, Xue, Zhongyun Zhao, Beth Barber, et al.. (2010). Cost of illness in patients with metastatic colorectal cancer. Journal of Medical Economics. 14(1). 1–9. 31 indexed citations
16.
Hunt, Ian, et al.. (2006). Is talc pleurodesis safe for young patients following primary spontaneous pneumothorax?. Interactive Cardiovascular and Thoracic Surgery. 6(1). 117–120. 32 indexed citations
17.
Davies, Alison, et al.. (2005). Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom*. Anaesthesia. 60(2). 155–162. 38 indexed citations
18.
Zhao, Zhongyun, M. Namjoshi, Beth Barber, et al.. (2004). Economic Outcomes Associated with Switching Individuals with Schizophrenia Between Risperidone and Olanzapine. CNS Drugs. 18(3). 157–164. 7 indexed citations
19.
Lage, Maureen J., Beth Barber, Patrick L. McCollam, Mohan Bala, & Joel Scherer. (2001). Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients. Catheterization and Cardiovascular Interventions. 53(3). 296–303. 7 indexed citations
20.
Chernow, Bart, et al.. (1983). Gastroesophageal fundoplication improves symptoms in refractory asthma.. PubMed. 49(7). 403–4. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shari Goldfarb Breakdown of academic impact, for papers by Jennifer Sung Breakdown of academic impact, for papers by Peg Esper Breakdown of academic impact, for papers by Maurizio Belfiglio Breakdown of academic impact, for papers by Alan S. Morrison Breakdown of academic impact, for papers by Ryszard Gellert Breakdown of academic impact, for papers by Eberhard Varenhorst Breakdown of academic impact, for papers by Roland T. Skeel Breakdown of academic impact, for papers by Peter T. Silberstein Breakdown of academic impact, for papers by Shawn Malone
Rankless by CCL
2026